Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Schedule Investigation of B-Cell Maturation Antigen (BCMA) Bispecific Antibody, Elranatamab, for Treatment of Newly Diagnosed Light Chain Amyloidosis

NCT07524634 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT07524634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07524634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Schedule Investigation of B-Cell Maturation Antigen (BCMA) Bispecific Antibody, Elranatamab, for Treatment of Newly Diagnosed Light Chain Amyloidosis
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
June 30, 2031
Enrollment
64 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid light-chain amyloidosis